Daiichi Sankyo Company, Limited

Hidenori Yano

Daisuke Nishimiya

Ryuji Hashimoto

Shinji Yamaguchi

Hidenori Takahashi

Shiho Ofuchi

Yoichi Niitsu

The present invention provides a novel peptide that has an amino acid sequence represented by SEQ ID NO: 18, and binds to an active protease but does not bind to a pro-protease.

Conjugate comprising an active MMP-9-binding peptide

SPINK2 mutant peptide conjugates are provided that inhibit KLK5. The KLK5 inhibitory peptide conjugates are Fc fusion peptides in which, in certain embodiments, the Fc region of the fusion peptides are the Fc region of human IgG1 or a fragment thereof. The KLK5 inhibitory peptide conjugates include an amino acid sequence of one of SEQ ID NOs: 34, 36, 38, 40, 42, 44, 46, 48, 96, 50, 52, 54, 56, 58, or 60. Pharmaceutical compositions that include the KLK5 inhibitory peptide conjugates useful for treating KLK5-related diseases are also provided.

KLK5 inhibitory peptide

Active MMP9-binding peptide

Growing community of inventors

Ota-ku, Japan

Hidenori Yano